As of 29 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder for injection in 150 mg and 450 mg vial] + paclitaxel [6 mg/mL solution for IV infusion] for the treatment of metastatic, persistent or recurrent cervical cancer. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 29 September to 13 October 2026.

As a preliminary recommendation, the HTA Council recommends the government financing of bevacizumab [100 mg/4 mL (25 mg/mL) and 400 mg/16 mL (25 mg/mL) Concentrate for Solution for Intravenous Infusion] in combination with a platinum-based doublet chemotherapy, specifically cisplatin + paclitaxel or carboplatin + paclitaxel for the treatment of metastatic, persistent, or recurrent cervical cancer, regardless of tumor histology, who require first-line systemic therapy, including patients presenting with metastatic cervical cancer at initial diagnosis with the following forms:

• Cisplatin [1 mg/mL solution for IV infusion] in 10 mL and 50 mL vial
• Carboplatin [10 mg/mL solution for IV infusion] in 15 mL and 45 mL vial; [lyophilized powder for injection] in 150 mg and 450 mg vial
• Paclitaxel [6 mg/mL solution for IV infusion] in 5 mL, 16.7 mL, 17 mL, 25 mL, and 43.4 mL vial

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 13 October 2026 (Tuesday) using the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline, shall not be entertained.